H. Mellstedt

发表

Tumor-associated antigens common to humans and chemically induced colonic tumors of the rat.

C. Rubio, J. Shetye, U. Harmenberg, 1990, Cancer research.

Immune response, depression and fatigue in relation to support intervention in mammary cancer patients

M. Lekander, H. Mellstedt, L. Bergkvist, 2007, Supportive Care in Cancer.

Therapeutic vaccines for cancer: an overview of clinical trials

I. Melero, H. Mellstedt, N. Thatcher, 2014, Nature Reviews Clinical Oncology.

Mucin 1-specific active cancer immunotherapy with tecemotide (L-BLP25) in patients with multiple myeloma: An exploratory study

H. Mellstedt, A. von Heydebreck, A. Österborg, 2014, Human vaccines & immunotherapeutics.

Epithelial cell adhesion molecule expression (CD326) in cancer: a short review.

H. Mellstedt, C. Patriarca, R. Macchi, 2012, Cancer treatment reviews.

Clinical results of vaccine therapy for cancer: learning from history for improving the future.

H. Mellstedt, P. Kokhaei, A. Choudhury, 2006, Advances in cancer research.

Towards therapeutic vaccines for colorectal carcinoma: a review of clinical trials

H. Mellstedt, B. Nilsson, Szilvia Mosolits, 2005, Expert review of vaccines.

Targeting human Ep‐CAM in transgenic mice by anti‐idiotype and antigen based vaccines

J. Fagerberg, H. Mellstedt, F. Campbell, 2004, International journal of cancer.

DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients

H. Mellstedt, B. Wahrén, P. Blomberg, 2017 .

NK-cell and T-cell functions in patients with breast cancer: effects of surgery and adjuvant chemo- and radiotherapy

M. Lekander, H. Mellstedt, B. Nilsson, 2007, British Journal of Cancer.

Fundamentals of tumor immunology

H. Mellstedt, A. Choudhury, H. Harlin, 2007 .

Functional HLA-DR T cell epitopes of CEA identified in patients with colorectal carcinoma immunized with the recombinant protein CEA

J. Fagerberg, H. Mellstedt, G. Ullenhag, 2004, Cancer Immunology, Immunotherapy.

Induction of IgG subclass responses in colorectal carcinoma patients vaccinated with recombinant carcinoembryonic antigen.

H. Mellstedt, G. Ullenhag, K. Strigård, 2002, Cancer research.

T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil

H. Mellstedt, A. Choudhury, 2006, Cancer Immunology, Immunotherapy.

Restricted T cell receptor V-β and J-β usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas

E. Halapi, R. Kiessling, H. Mellstedt, 2005, Cancer Immunology, Immunotherapy.

Oligoclonal T Cells Expressing the TCR V-ß 6 Gene Product Following IL-2 Culture of Ovarian Carcinoma Derived Lymphocytes

E. Halapi, R. Kiessling, H. Mellstedt, 1992 .

Diverse effect of cytokine treatment of tumor cells on specific versus non-specific cytotoxicity

E. Halapi, R. Kiessling, H. Mellstedt, 1992, Medical oncology and tumor pharmacotherapy.

Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen

J. Fagerberg, H. Mellstedt, B. Wahrén, 1998, Cancer Immunology, Immunotherapy.

Restricted T cell receptor V-beta and J-beta usage in T cells from interleukin-2-cultured lymphocytes of ovarian and renal carcinomas.

E. Halapi, R. Kiessling, H. Mellstedt, 1993, Cancer immunology, immunotherapy : CII.

Granulocyte-monocyte-colony-stimulating factor augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity

H. Mellstedt, P. Wersäll, G. Masucci, 2004, Cancer Immunology, Immunotherapy.

Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients.

H. Mellstedt, F. Mozaffari, J. Frödin, 2014, International journal of oncology.

Generation of human LAK cells in tissue culture bags using recombinant IL-2 and serum free medium. Effects of pretreatment with phenylalanine-methylester.

H. Mellstedt, I. Cotgreave, H. Wigzell, 1990, Acta oncologica.

Keynote comment: deliberations of a born-again cancer immunotherapist.

H. Mellstedt, 2006, The Lancet. Oncology.

Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 andα-IFN

H. Mellstedt, P. Wersäll, H. Mellstedt, 1995, Medical oncology.

Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein

H. Mellstedt, G. Ullenhag, B. Wahrén, 2012, Journal of Clinical Immunology.

Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVAC-KSA) and granulocyte macrophage colony- stimulating factor induced a tumor-specific cellular immune response.

H. Mellstedt, G. Ullenhag, P. Moingeon, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

FcγR polymorphisms and clinical outcome in colorectal cancer patients receiving passive or active antibody treatment.

H. Mellstedt, P. Kokhaei, Biyun Wang, 2010, International journal of oncology.

Treatment with GM-CSF and IL-2 in patients with metastatic colorectal carcinoma induced high serum levels of neopterin and sIL-2R, an indicator of immune suppression

H. Mellstedt, P. Wersäll, P. Ragnhammar, 2002, Cancer Immunology, Immunotherapy.

Immunogenic regions of the GA733–2 tumour-associated antigen recognised by autoantibodies of patients with colorectal carcinoma

J. Fagerberg, U. Harmenberg, H. Mellstedt, 2002, Cancer Immunology, Immunotherapy.

Interleukin-4 augments the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity

H. Mellstedt, P. Wersäll, G. Masucci, 2005, Cancer Immunology, Immunotherapy.

Influence of varying doses of granulocyte-macrophage colony-stimulating factor on pharmacokinetics and antibody-dependent cellular cytotoxicity

H. Mellstedt, B. Nilsson, J. Frödin, 2008, Cancer Immunology, Immunotherapy.

Granulocyte-monocyte colony-stimulating-factor augments the interleukin-2-induced cytotoxic activity of human lymphocytes in the absence and presence of mouse or chimeric monoclonal antibodies (mAb 17-1A)

H. Mellstedt, P. Wersäll, G. Masucci, 2005, Cancer Immunology, Immunotherapy.

Lymphokine activated killer (LAK) cells in antibody dependent cellular cytotoxicity (ADCC) using MAb 17-1A: a combination of potential usefulness in tumor therapy.

J. Nielsen, H. Mellstedt, H. Wigzell, 1989, Hybridoma.

Development of a technology platform for large-scale clinical grade production of DC.

H. Mellstedt, P. Pisa, G. Masucci, 2004, Cytotherapy.

Simplified long term large scale production of highly active human lak cells for therapy

H. Mellstedt, P. Wersäll, G. Masucci, 1990, Medical oncology and tumor pharmacotherapy.

Interferons in the treatment of multiple myeloma.

B. Klein, D. Huhn, R. Bataille, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

T-cell receptor BV gene usage in colorectal carcinoma patients immunised with recombinant Ep-CAM protein or anti-idiotypic antibody

J. Fagerberg, H. Mellstedt, M. Jeddi-Tehrani, 2005, Cancer Immunology, Immunotherapy.

Induction of a T‐ and B‐cell response against a unique amino acid sequence of the mouse IgG2A hinge region in a MAb‐treated patient

J. Fagerberg, H. Mellstedt, P. Wersäll, 1997, International journal of cancer.

Spectrum of cytokeratin-positive cells in the bone marrows of colorectal carcinoma patients.

J. Shetye, H. Mellstedt, S. Emdin, 2004, Anticancer research.

Systemic immune effects of adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide and/or radiotherapy in breast cancer: a longitudinal study

M. Lekander, H. Mellstedt, L. Bergkvist, 2008, Cancer Immunology, Immunotherapy.

Overcoming immunosuppressive mechanisms.

H. Mellstedt, F. Mozaffari, A. Choudhury, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Normal colon of Sprague-Dawley rats

C. Rubio, J. Shetye, H. Mellstedt, 2004, Anatomy and Embryology.

Biologic therapeutics as the fourth modality in cancer treatment.

H. Mellstedt, G. Masucci, 1990, Leukemia.

Chemotherapy and immunotherapy of colorectal cancer

J. Fagerberg, H. Mellstedt, A. Österborg, 1991, Medical oncology and tumor pharmacotherapy.

Granulocyte/macrophage-colony-stimulating factor augments the induction of antibodies, especially anti-idiotypic antibodies, to therapeutic monoclonal antibodies

J. Fagerberg, L. Hansson, H. Mellstedt, 1995, Cancer Immunology, Immunotherapy.

Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma

P. Wersäll, H. Mellstedt, P. Biberfeld, 1997, Cancer Immunology, Immunotherapy.

Idiotypic network responses and anti-idiotypes in cancer therapy.

J. Fagerberg, H. Mellstedt, 1997 .

Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A

J. Fagerberg, H. Mellstedt, P. Ragnhammar, 1996, Cancer Immunology, Immunotherapy.

Cancer Immunotherapy Confers a Global Benefit

H. Mellstedt, N. Rezaei, Z. Aryan, 2020, Cancer Immunology.

Vaccination in gastrointestinal cancer

H. Mellstedt, M. Liljefors, K. Sundqvist, 2014 .

Autoantibodies against the tumour-associated antigen GA733-2 in patients with colorectal carcinoma

Jan Fagerberg, J. Fagerberg, U. Harmenberg, 1999, Cancer Immunology, Immunotherapy.

T‐cell‐epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma

J. Fagerberg, U. Harmenberg, H. Mellstedt, 1999, International journal of cancer.

Gene expression analysis using long-term preserved formalin-fixed and paraffin-embedded tissue of non-small cell lung cancer.

H. Mellstedt, J. Lundahl, Therese A. S. Jacobson, 2011, International journal of oncology.

Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin

H. Mellstedt, D. Wion, R. Kast, 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

Awareness and understanding of cancer immunotherapy in Europe

I. Melero, H. Mellstedt, N. Thatcher, 2014, Human vaccines & immunotherapeutics.

Awareness and understanding of cancer immunotherapy in Europe.

I. Melero, H. Mellstedt, N. Thatcher, 2013 .

Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer

C. Denkert, S. Darb-Esfahani, H. Mellstedt, 2014, Journal of gynecologic oncology.

Expression of Epithelial Cell Adhesion Molecule in Paired Tumor Samples of Patients With Primary and Recurrent Serous Ovarian Cancer

C. Denkert, S. Darb-Esfahani, H. Mellstedt, 2013, International Journal of Gynecologic Cancer.

Durable Carcinoembryonic Antigen (CEA)-Specific Humoral and Cellular Immune Responses in Colorectal Carcinoma Patients Vaccinated with Recombinant CEA and Granulocyte/Macrophage Colony-Stimulating Factor

H. Mellstedt, G. Ullenhag, M. Jeddi-Tehrani, 2004, Clinical Cancer Research.

The future of cancer vaccines for non-small-cell lung cancer: ongoing trials.

H. Mellstedt, A. Choudhury, M. Palma, 2008, Clinical lung cancer.

A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib‐resistant ROR1+ CLL cells

H. Mellstedt, J. Schultz, A. Österborg, 2021, EJHaem.

BK virus (BKV) quantification in urine samples of bone marrow transplanted patients is helpful for diagnosis of hemorrhagic cystitis, although wide individual variations exist.

H. Mellstedt, G. Bogdanovic, P. Kokhaei, 2003, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Dendritic cells, pulsed with lysate of allogeneic tumor cells, are capable of stimulating MHC-restricted antigen-specific antitumor T cells

H. Mellstedt, P. Kokhaei, A. Choudhury, 2006, Medical oncology.

Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17‐1A

H. Mellstedt, B. Nilsson, P. Ragnhammar, 2003, International journal of cancer.

ESMO at 30: mission ongoing.

H. Mellstedt, P. Kosmidis, H. Ludwig, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Gene therapy for glioblestome multiforme: in vivo tumor transduction with the herpes simplex thymidine kinase gene followed by ganciclovir

O. Witte, L. Mariani, J. Villemure, 1997, Journal of Molecular Medicine.

Vaccination with Ep-CAM Protein or Anti-Idiotypic Antibody Induces Th1-Biased Response against MHC Class I- and II-Restricted Ep-CAM Epitopes in Colorectal Carcinoma Patients

J. Fagerberg, H. Mellstedt, M. Steinitz, 2004, Clinical Cancer Research.

RECOMBINANT CARCINOEMBRYONIC ANTIGEN AND GRANULOCY-TE-MACROPHAGE COLONY-STIMULATING FACTOR FOR ACTIVE IMMUNIZATION OF COLORECTAL CARCINOMA PATIENTS

J. Fagerberg, H. Mellstedt, B. Wahrén, 1995 .

Implications of the development of biosimilars for cancer treatment.

H. Mellstedt, 2010, Future oncology.

Clinical considerations for biosimilar antibodies

H. Mellstedt, 2013, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

Induction of IgM, IgA and IgE Antibodies in Colorectal Cancer Patients Vaccinated with a Recombinant CEA Protein

H. Mellstedt, G. Ullenhag, B. Wahrén, 2012, Journal of Clinical Immunology.

MAb17-1A and cytokines for the treatment of patients with colorectal carcinoma.

Jan Fagerberg, J. Fagerberg, H. Mellstedt, 2002, Hybridoma and hybridomics.

Biosimilars – terms of use

H. Mellstedt, S. Danese, P. Declerck, 2015, Current medical research and opinion.

Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer

H. Mellstedt, G. Ullenhag, F. Mozaffari, 2017, PloS one.

Principles of immunology: an overview of basic immunology

A Choudhury, H Mellstedt, H Harlin, 2007 .

National integration of European standards.

H. Mellstedt, E. Bajetta, A. Gevorgyan, 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer in developing countries: challenges and solutions.

H. Mellstedt, A. Reeler, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Retrieval of leukocyte antigens in paraffin-embedded rat tissues.

A. Scheynius, J. Shetye, H. Mellstedt, 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Combinations of IL-2, GM-CSF, IL-4, IFN-α and TNF-α increase the antibody dependent cellular cytotoxicity (ADCC) of blood mononuclear cells in presence of either mouse or chimeric MAb 17-1A : a preclinical evaluation

H. Mellstedt, G. Masucci, 1991 .

ESMO minimum clinical recommendations--the beginning of a process.

R. Stahel, H. Mellstedt, L. Jost, 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

Immunization Effect of Monoclonal Antibodies against Tumor‐Associated Antigens during Cancer Treatment

J. Fagerberg, H. Mellstedt, H. Wigzell, 1993, Annals of the New York Academy of Sciences.

European Perspective on Biosimilars.

H. Mellstedt, 2017, Journal of oncology practice.

GM-CSF Augments the IL-4 Induced Cytotoxic Activity of Human Peripheral Blood Mononuclear Cells in the Presence of the Mouse Monoclonal Antibody 17–1A

H. Mellstedt, S. Traniello, E. Reali, 1993 .

The challenge of biosimilars.

D. Niederwieser, H. Mellstedt, H. Ludwig, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Therapeutic vaccination in patients with gastrointestinal malignancies. A review of immunological and clinical results.

H. Mellstedt, G. Ullenhag, H. Mellstedt, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Introduction: ASCO-ESMO consensus statement on quality cancer care.

S. Horning, H. Mellstedt, Sandra J. Horning, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical effects of a chimeric anti-EpCAM monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor in patients with metastatic colorectal carcinoma.

J. Fagerberg, H. Mellstedt, B. Nilsson, 2005, International journal of oncology.

Therapeutic vaccines for cancer: an overview of clinical trials

I. Melero, H. Mellstedt, N. Thatcher, 2014, Nature Reviews Clinical Oncology.

Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients.

H. Mellstedt, F. Mozaffari, J. Frödin, 2014, International journal of oncology.

H. Mellstedt, G. Ullenhag, M. Jeddi-Tehrani, 2004, Clinical Cancer Research.

Cancer initiatives in developing countries.

H. Mellstedt, H. Mellstedt, 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

GM-CSF augments the IL-4-induced cytotoxic activity of human mononuclear cells in the presence of the mouse monoclonal antibody 17-1A

H. Mellstedt, G. Masucci, E. Reali, 1993 .

ESMO Handbook on Principles of Translational Research

Dirk Schrijvers, Hakan Mellstedt, Dimitrios Bafaloukos, 2007 .